Advertisement

Relevant Trials Update in Sarcomas and Gastrointestinal Stromal Tumors

What Surgeons Should Know

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Surgical Oncology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bonvalot S.
        • Gronchi A.
        • Le Péchoux C.
        • et al.
        Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): A multicentre, open-label, randomised, phase 3 trial.
        Lancet Oncol. 2020; 21: 1366-1377
        • Bonvalot S.
        • Rutkowski P.L.
        • Thariat J.
        • et al.
        NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (act.in.sarc): A multicentre, phase 2-3, randomised, controlled trial.
        Lancet Oncol. 2019; 20: 1148-1159
        • Gronchi A.
        • Palmerini E.
        • Quagliuolo V.
        • et al.
        Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Final results of a randomized trial from italian (ISG), spanish (GEIS), french (FSG), and polish (PSG) sarcoma groups.
        J Clin Oncol. 2020; 38: 2178-2186
        • Callegaro D.
        • Miceli R.
        • Bonvalot S.
        • et al.
        Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: Retrospective analysis across major histological subtypes and major reference centres.
        Eur J Cancer. 2018; 105: 19-27
        • Lansu J.
        • Bovée J.V.M.G.
        • Braam P.
        • et al.
        Dose reduction of preoperative radiotherapy in myxoid liposarcoma: A nonrandomized controlled trial.
        JAMA Oncol. 2021; 7: e205865
        • Sarcoma Meta-analysis Collaboration (SMAC)
        Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults.
        Cochrane Database Syst Rev. 2000; 4: CD001419
        • Pervaiz N.
        • Colterjohn N.
        • Farrokhyar F.
        • et al.
        A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma.
        Cancer. 2008; 113: 573-581
        • Pasquali S.
        • Pizzamiglio S.
        • Touati N.
        • et al.
        The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: Revisiting the results of the EORTC-STBSG 62931 randomised trial.
        Eur J Cancer. 2019; 109: 51-60
        • Pasquali S.
        • Palmerini E.
        • Quagliuolo V.
        • et al.
        Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial.
        Cancer. 2022; 128: 85-93
        • Gronchi A.
        • Ferrari S.
        • Quagliuolo V.
        • et al.
        Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): An international, open-label, randomised, controlled, phase 3, multicentre trial.
        Lancet Oncol. 2017; 18: 812-822
      1. DIGITAL FOREST srl. Applestore.
        (Available at:) (Accessed February 18, 2022)
        • Bonvalot S.
        • Le Pechoux C.
        • De Baere T.
        • et al.
        First-in-human study testing a new radioenhancer using nanoparticles (NBTXR3) activated by radiation therapy in patients with locally advanced soft tissue sarcomas.
        Clin Cancer Res. 2017; 23: 908-917
        • Wardelmann E.
        • Haas R.L.
        • Bovée J.V.
        • et al.
        Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the european organization for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC-STBSG) recommendations for pathological examination and reporting.
        Eur J Cancer. 2016; 53: 84-95
        • O'Sullivan B.
        • Davis A.M.
        • Turcotte R.
        • et al.
        Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: A randomised trial.
        Lancet. 2002; 359: 2235-2241
        • Rosenberg S.A.
        • Tepper J.
        • Glatstein E.
        • et al.
        The treatment of soft-tissue sarcomas of the extremities: Prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy.
        Ann Surg. 1982; 196: 305-315
        • Pisters P.W.
        • Harrison L.B.
        • Leung D.H.
        • et al.
        Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma.
        J Clin Oncol. 1996; 14: 859-868
        • Yang J.C.
        • Chang A.E.
        • Baker A.R.
        • et al.
        Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity.
        J Clin Oncol. 1998; 16: 197-203
        • Beane J.D.
        • Yang J.C.
        • White D.
        • et al.
        Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial.
        Ann Surg Oncol. 2014; 21: 2484-2489
        • Davis A.M.
        • O'Sullivan B.
        • Turcotte R.
        • et al.
        Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma.
        Radiother Oncol. 2005; 75: 48-53
        • Kraybill W.G.
        • Harris J.
        • Spiro I.J.
        • et al.
        Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation therapy oncology group trial 9514.
        J Clin Oncol. 2006; 24: 619-625
        • Kraybill W.G.
        • Harris J.
        • Spiro I.J.
        • et al.
        Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation therapy oncology group trial 9514.
        Cancer. 2010; 116: 4613-4621
        • Woll P.J.
        • Reichardt P.
        • Le Cesne A.
        • et al.
        Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): A multicentre randomised controlled trial.
        Lancet Oncol. 2012; 13: 1045-1054
        • Gronchi A.
        • Stacchiotti S.
        • Verderio P.
        • et al.
        Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): Long-term follow-up of a randomized clinical trial from the italian sarcoma group and the spanish sarcoma group.
        Ann Oncol. 2016; 27: 2283-2288
        • Blanke C.D.
        • Demetri G.D.
        • von Mehren M.
        • et al.
        Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
        J Clin Oncol. 2008; 26: 620-625
        • Demetri G.D.
        • van Oosterom A.T.
        • Garrett C.R.
        • et al.
        Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial.
        Lancet. 2006; 368: 1329-1338
        • Demetri G.D.
        • Reichardt P.
        • Kang Y.K.
        • et al.
        Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international, multicentre, randomised, placebo-controlled, phase 3 trial.
        Lancet. 2013; 381: 295-302
        • Blay J.Y.
        • Serrano C.
        • Heinrich M.C.
        • et al.
        Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): A double-blind, randomised, placebo-controlled, phase 3 trial.
        Lancet Oncol. 2020; 21: 923-934
        • Kang Y.K.
        • George S.
        • Jones R.L.
        • et al.
        Avapritinib versus regorafenib in locally advanced unresectable or metastatic GI stromal tumor: A randomized, open-label phase III study.
        J Clin Oncol. 2021; 39: 3128-3139
        • DeMatteo R.P.
        • Lewis J.J.
        • Leung D.
        • et al.
        Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival.
        Ann Surg. 2000; 231: 51-58
        • Joensuu H.
        • Eriksson M.
        • Sundby Hall K.
        • et al.
        One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: A randomized trial.
        JAMA. 2012; 307: 1265-1272
        • Joensuu H.
        • Eriksson M.
        • Sundby Hall K.
        • et al.
        Survival outcomes associated with 3 years vs 1 year of adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: An analysis of a randomized clinical trial after 10-year follow-up.
        JAMA Oncol. 2020; 6: 1241-1246
        • Dematteo R.P.
        • Ballman K.V.
        • Antonescu C.R.
        • et al.
        Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, double-blind, placebo-controlled trial.
        Lancet. 2009; 373: 1097-1104
        • Raut C.P.
        • Espat N.J.
        • Maki R.G.
        • et al.
        Efficacy and tolerability of 5-year adjuvant imatinib treatment for patients with resected intermediate- or high-risk primary gastrointestinal stromal tumor: The PERSIST-5 clinical trial.
        JAMA Oncol. 2018; 4: e184060
        • Eisenberg B.L.
        • Harris J.
        • Blanke C.D.
        • et al.
        Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665.
        J Surg Oncol. 2009; 99: 42-47
        • Wang D.
        • Zhang Q.
        • Blanke C.D.
        • et al.
        Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: Long-term follow-up results of radiation therapy oncology group 0132.
        Ann Surg Oncol. 2012; 19: 1074-1080
        • Choi H.
        • Charnsangavej C.
        • Faria S.C.
        • et al.
        Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria.
        J Clin Oncol. 2007; 25: 1753-1759
        • DeMatteo R.P.
        • Ballman K.V.
        • Antonescu C.R.
        • et al.
        Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (alliance) intergroup phase 2 trial.
        Ann Surg. 2013; 258: 422-429
        • Corless C.L.
        • Ballman K.V.
        • Antonescu C.R.
        • et al.
        Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: The ACOSOG Z9001 trial.
        J Clin Oncol. 2014; 32: 1563-1570
        • Joensuu H.
        • Eriksson M.
        • Sundby Hall K.
        • et al.
        Adjuvant imatinib for high-risk GI stromal tumor: Analysis of a randomized trial.
        J Clin Oncol. 2016; 34: 244-250
        • Casali P.G.
        • Le Cesne A.
        • Poveda Velasco A.
        • et al.
        Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: A european organisation for research and treatment of cancer soft tissue and bone sarcoma group intergroup randomized trial in collaboration with the australasian gastro-intestinal trials group, UNICANCER, french sarcoma group, italian sarcoma group, and spanish group for research on sarcomas.
        J Clin Oncol. 2015; 33: 4276-4283
        • McAuliffe J.C.
        • Hunt K.K.
        • Lazar A.J.
        • et al.
        A randomized, phase II study of preoperative plus postoperative imatinib in GIST: Evidence of rapid radiographic response and temporal induction of tumor cell apoptosis.
        Ann Surg Oncol. 2009; 16: 910-919
        • Du C.Y.
        • Zhou Y.
        • Song C.
        • et al.
        Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: A prospective randomised trial in china.
        Eur J Cancer. 2014; 50: 1772-1778
        • Sindelar W.F.
        • Kinsella T.J.
        • Chen P.W.
        • et al.
        Intraoperative radiotherapy in retroperitoneal sarcomas. final results of a prospective, randomized, clinical trial.
        Arch Surg. 1993; 128: 402-410
        • Robertson J.M.
        • Sondak V.K.
        • Weiss S.A.
        • et al.
        Preoperative radiation therapy and iododeoxyuridine for large retroperitoneal sarcomas.
        Int J Radiat Oncol Biol Phys. 1995; 31: 87-92
        • Jones J.J.
        • Catton C.N.
        • O'Sullivan B.
        • et al.
        Initial results of a trial of preoperative external-beam radiation therapy and postoperative brachytherapy for retroperitoneal sarcoma.
        Ann Surg Oncol. 2002; 9: 346-354
        • Smith M.J.
        • Ridgway P.F.
        • Catton C.N.
        • et al.
        Combined management of retroperitoneal sarcoma with dose intensification radiotherapy and resection: Long-term results of a prospective trial.
        Radiother Oncol. 2014; 110: 165-171
        • Pisters P.W.
        • Ballo M.T.
        • Fenstermacher M.J.
        • et al.
        Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma.
        J Clin Oncol. 2003; 21: 3092-3097
        • Roeder F.
        • Ulrich A.
        • Habl G.
        • et al.
        Clinical phase I/II trial to investigate preoperative dose-escalated intensity-modulated radiation therapy (IMRT) and intraoperative radiation therapy (IORT) in patients with retroperitoneal soft tissue sarcoma: Interim analysis.
        BMC Cancer. 2014; 14 (617-2407-14-617)
        • Gronchi A.
        • De Paoli A.
        • Dani C.
        • et al.
        Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: A phase I-II study from the italian sarcoma group.
        Eur J Cancer. 2014; 50: 784-792